On September 5, 2025, the Health Insurance Fund of the Federation of Bosnia and Herzegovina failed to deliver the following medicines to the University Clinical Center Tuzla: – Azacitidine – Cytarabine – Exemestane – Entecavir – Irinotecan – Carboplatin – Megestrol tablets – Nilotinib 200 mg – Oxaliplatin – Rixathon -Sunitinib 25 mg -Tamoxifen
Ramiz Salkić, member of the National Assembly of Republika Srpska, visited the University Clinical Center Tuzla (UKC Tuzla), where he met with Director Prof. Dr. Šekib Umihanić. The discussion emphasized the vital role of UKC Tuzla in providing healthcare services to returnees in Republika Srpska, as well as the institution’s exceptional importance during the annual…
As part of advancing radiotherapy procedures, the Clinic for Oncology and Radiotherapy of the University Clinical Center Tuzla (UKC Tuzla) has introduced the state-of-the-art C-RAD system for verification and monitoring of radiation exposure. This innovative technology represents a significant step toward more precise and safer treatment of patients with malignant diseases, ensuring maximum protection of…
At the University Clinical Center Tuzla (UKC Tuzla), a press conference was held to present a new advancement in vascular surgery for the treatment of aortic aneurysms, performed at the Clinic for Cardiovascular Surgery. The innovative procedure in open surgery for giant aortoiliac aneurysms, which preserves hypogastric artery flow, was developed by Prof. Dr. Dragan…
At the University Clinical Center Tuzla (UKC Tuzla), contracts were officially signed with eleven young doctors who will begin their specialization in the fields of anesthesiology, internal medicine, and microbiology. The contract signing ceremony was attended by the Director of UKC Tuzla, Prof. Dr. Šekib Umihanić, Head of the Legal Affairs and Human Resources Sector…